Aditya Birla Sun Life Pharma & Healthcare Fund
An open ended equity scheme investing in Pharma and Healthcare Services Sector
July 2026
| Equity Scheme |  |
 |
 |
 |
An open ended equity scheme investing in Pharma and Healthcare Services Sector
July 2026
| Equity Scheme | |
|
|
|
| Investment Objective | |
| The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved | |
| Fund Category: Sectoral/Thematic | |
 |
|
| Fund Snapshot | |
| Date of Allotment : Jul 11, 2019 | |
| Benchmark: BSE Healthcare TRI | |
| Fund Manager -Mr. Dhaval Shah Managing the Fund Since: July 11, 2019 Experience in Managing the Fund: 7.1 Years |
|
| SIP: Daily/Weekly/Monthly: Minimum ₹ 100/-and in multiples of ₹ 1/- thereafter |
|
| Application Amount for fresh subscription: ₹ 1000 (plus in multiplies of ₹ 1) |
|
| Minimum Additional Investment: ₹ 1000 (plus in multiplies of ₹ 1) |
|
| Load Structure (as % of NAV) (Incl. for SIP) | |
| Entry Load: | NIL |
| Exit Load: | For redemption/switch-out of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil |
| Count of Securities: 38 | |
| AUM as on July 31, 2026 (in ₹Crore) | |
| Month End AUM | 1,073.85 |
| Monthly Average AUM | 1,044.97 |
| Base Expense Ratio (BER) | |
| Regular | 1.90% |
| Direct | 0.80% |
| BER excludes brokerage incurred towards execution of trades, transaction cost & statutory levies as applicable to investors. | |
| NAV as on July 31, 2026 | |
| Regular Growth | 36.41 |
| Regular IDCW$ | 24.04 |
| Direct Growth | 40.52 |
| Direct IDCW$ | 26.35 |
| $Income Distribution cum capital withdrawal | |
| Valuation Parameters | |
| Average P/E | 41.8 |
| Average P/BV | 6.93 |
| Average Dividend Yield | 0.69 |
| Sectoral Contribution(in %) |
 |
| Market Capitalisation |
 |
| Volatility Measures | |
| Portfolio Turnover | 0.19 |
| Standard Deviation | 15.30% |
| Sharpe Ratio | 1.01 |
| Beta | 0.91 |
| Treynor Ratio | 0.18 |
| Information Ratio | -0.45 |
Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk FreeRate assumed tobe 5.41%(FBIL OvernightMIBOR as on 31 July, 2026) for calculating SharpeRatio
| Rating Profile of Portfolio |  |
| Sector/Issuer Name | % of Total AUM |
% of Derivatives |
% of Net AUM |
| Equity & Equity Related | |||
| Pharmaceuticals & Biotechnology | 74.19% | ||
| ● Torrent Pharmaceuticals Ltd. | 9.94% | ||
| ● Sun Pharmaceutical Industries Ltd. | 9.75% | ||
| ● Cipla Ltd. | 4.56% | ||
| ● Aurobindo Pharma Ltd. | 4.29% | ||
| ● Ajanta Pharmaceuticals Ltd. | 4.17% | ||
| ● Sai Life Sciences Ltd. | 3.89% | ||
| ● Mankind Pharma Ltd. | 3.58% | ||
| ● Lupin Ltd. | 3.51% | ||
| ● Abbott India Ltd. | 3.35% | ||
| Emcure Pharmaceuticals Ltd. | 3.24% | ||
| Ipca Laboratories Ltd. | 2.47% | ||
| Gland Pharma Ltd. | 2.34% | ||
| Shilpa Medicare Ltd. | 2.32% | ||
| CORONA Remedies Ltd. | 2.29% | ||
| Procter & Gamble Health Ltd. | 2.16% | ||
| Divi''s Laboratories Ltd. | 1.95% | ||
| Alkem Laboratories Ltd. | 1.88% | ||
| Sanofi Consumer Healthcare India Ltd. | 1.36% | ||
| Pfizer Ltd. | 1.26% | ||
| Biocon Ltd. | 1.26% | ||
| Piramal Pharma Ltd. | 1.16% | ||
| Anthem Biosciences Ltd. | 1.07% | ||
| Dr. Reddy''s Laboratories Ltd. | 1.06% | ||
| Glaxosmithkline Pharmaceuticals Ltd. | 0.80% | ||
| Jubilant Pharmova Ltd. | 0.55% | ||
| Healthcare Services | 21.78% | ||
| ● Apollo Hospitals Enterprise Ltd. | 7.08% | ||
| Fortis Healthcare Ltd. | 2.98% | ||
| Dr. Lal Path Labs Ltd. | 2.12% | ||
| Jupiter Life Line Hospitals Ltd. | 2.03% | ||
| Thyrocare Technologies Ltd. | 1.91% | ||
| Metropolis Healthcare Ltd. | 1.59% | ||
| Vijaya Diagnostic Centre Ltd. | 0.98% | ||
| Manipal Health Enterprises Ltd | 0.89% | ||
| Suraksha Diagnostic Ltd. | 0.79% | ||
| Max Healthcare Institute Ltd. | 0.72% | ||
| Syngene International Ltd. | 0.68% | ||
| Insurance | 0.87% | ||
| Medi Assist Healthcare Services Ltd. | 0.87% | ||
| Chemicals & Petrochemicals | 0.78% | ||
| Vinati Organics Ltd. | 0.78% | ||
| Net Cash and Cash Equivalent | 2.39% | ||
| Grand Total | 100.00% |
Miscellaneous includes securities with exposure of less than 0.01%
| Scheme Name | |
| Aditya Birla Sun Life Pharma & Healthcare Fund An open ended equity scheme investing in Pharma and Healthcare Services Sector |
|
| This product is suitable for investors who are seeking*: | |
|
|
Risk-o-meter  |
Benchmark Risk-o-meter BSE Healthcare TRI  |
| *Investors should consult their financial advisors if in doubt whether the product is suitable for them. | |